Trial Profile
Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Taizhou Mabtech Pharmaceuticals
- 09 Apr 2024 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 18 Oct 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.
- 12 Nov 2021 Status changed from recruiting to active, no longer recruiting.